http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ndumiso Vukile Mdlovu,KUEN-SONG LIN,Meng-Tzu Weng,Chi-Cheng Hsieh,You-Sheng Lin,Maria Janina Carrera Espinoza 한국공업화학회 2021 Journal of Industrial and Engineering Chemistry Vol.102 No.-
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, accounting for about 75% of allliver cancers. It is the third most common basis for cancer mortality worldwide, and unfortunately, itstreatment is often limited by the shortage of appropriate therapeutic options and side effects causedby the current treatment methods. To overcome this, doxorubicin (DOX)-loaded pH-/thermoresponsivemagnetic mesoporous nanocarriers were formulated and evaluated for their in vitro anticanceractivity against HCC. These nanocarriers consist of iron oxide (IO) nanoparticles conjugated withSBA-15 (S15) and Pluronic F127 (PF) to form IOS15 nanocomposites and IOS15@PF nanocarriers. The preparednanocarriers were superparamagnetic with saturation magnetizations of IOS15 and IOS15@PFbeing 76.3 and 72.1 emu/g, respectively. Small-angle neutron/X-ray scattering (SANS/SAXS) studiesshowed that the developed nanocarriers are temperature-sensitive and possess hexagonally arrangedstructures. Cell viability studies demonstrated that IOS15@PF@DOX nanocomplexes induced more apoptosisor necrosis. A temperature (69% release after 48 h)- and pH (70% release after 48 h)-dependent DOXrelease was observed, whereby more DOX was released at a high temperature of 42 C and pH value of5.4. Thus, the developed nanocarriers possess great potential for use in the targeted delivery of conventionalchemotherapeutic drugs with enhanced efficiency.
Lan Ting-Yuan,Lin Yen-Chun,Tseng Tai-Chung,Yang Hung-Chih,Kao Jui-Hung,Cheng Chiao-Feng,Lee Tai-Ju,Huang Shang-Chin,Lu Cheng-Hsun,Li Ko-Jen,Hsieh Song-Chou 거트앤리버 소화기연관학회협의회 2023 Gut and Liver Vol.17 No.2
Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate in hepatitis B surface antigen (HBsAg)-negative patients receiving rituximab for autoimmune diseases in a large real-world cohort. Methods: From March 2006 to December 2019, 900 patients with negative HBsAg receiving at least one cycle of rituximab for autoimmune diseases in a tertiary medical center in Taiwan were retrospectively reviewed. Clinical outcome and factors associated with HBVr were analyzed. Results: After a median follow-up period of 3.3 years, 21 patients developed HBVr, among whom 17 patients were positive for hepatitis B core antibody (anti-HBc) and four were negative. Thirteen patients had clinical hepatitis flare, while eight patients had HBsAg seroreversion without hepatitis. Old age, anti-HBc positivity, undetectable serum hepatitis B surface antibody level at rituximab initiation and a higher average rituximab dose were associated with a higher HBVr rate. There was no significant difference in the HBVr risk between rheumatoid arthritis and other autoimmune diseases. Among anti-HBc-negative patients, subjects without HBV vaccination at birth had an increased risk of HBVr (4/368, 1.1%) compared with those who received vaccination (0/126, 0%). Conclusions: In HBV endemic areas where occult HBV is prevalent, anti-HBc-negative patients, may still be at risk for HBVr after rituximab exposure. HBVr may still be considered in HBsAgnegative patients developing abnormal liver function after rituximab exposure, even in patients with negative anti-HBc.